Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion type Assertion NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_head.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion description "[This study further provides a basis for clinical studies of the antisense oligonucleotide targeted to the RIalpha subunit of PKA (GEM 231) as a cancer therapeutic agent used alone or in combination with conventional chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_provenance.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion evidence source_evidence_literature NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_provenance.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion SIO_000772 10570186 NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_provenance.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion wasDerivedFrom befree-20150227 NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_provenance.
- NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_assertion wasGeneratedBy ECO_0000203 NP900824.RAxoyBtgyPcygCuGXekSv1_OzomoeIdjxSBKuB9g79oXU130_provenance.